AstraZeneca's vaccine has limited efficacy against South Africa variant – research

AstraZeneca's Covid-19 vaccine offers limited protection against mild infection of the South African variant (B.1.351). This is according to initial results of a study conducted by South Africa's University of Witwatersrand and Oxford University, with which AstraZeneca co-developed the vaccine. Oxford University and AstraZeneca are reportedly adapting the vaccine for the mutation and predict it will be ready by autumn.